2024
DOI: 10.1016/j.bioorg.2024.107101
|View full text |Cite
|
Sign up to set email alerts
|

Development of new thieno[2,3-d]pyrimidines as dual EGFR and STAT3 inhibitors endowed with anticancer and pro-apoptotic activities

Heba A. Elsebaie,
Tarek F. El-Moselhy,
Eman A. El-Bastawissy
et al.
Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
3
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
8

Relationship

2
6

Authors

Journals

citations
Cited by 8 publications
(3 citation statements)
references
References 64 publications
0
3
0
Order By: Relevance
“…When the ratio of proapoptotic proteins exceeds that of antiapoptotic proteins, several processes are triggered, and the outer mitochondrial membrane becomes permeable. A critical tumor suppressor gene associated with apoptosis is p53. Apoptosis mediated by p53 may be brought on by decreased Bcl-2 expression and activation of caspases 3 and 9.…”
Section: Resultsmentioning
confidence: 99%
“…When the ratio of proapoptotic proteins exceeds that of antiapoptotic proteins, several processes are triggered, and the outer mitochondrial membrane becomes permeable. A critical tumor suppressor gene associated with apoptosis is p53. Apoptosis mediated by p53 may be brought on by decreased Bcl-2 expression and activation of caspases 3 and 9.…”
Section: Resultsmentioning
confidence: 99%
“…These compounds have garnered attention due to their unique structural similarity to purines and their versatile pharmacological properties. They have been shown to possess antimicrobial [ 1 ], antiviral [ 2 ], and anti-inflammatory [ 3 , 4 ] properties, serve as β3-adrenoceptor agonists [ 5 ], exhibit anti-tuberculosis properties [ 6 ], antiprotozoal activity [ 7 ], and kinase inhibition [ 8 , 9 , 10 , 11 , 12 ], act as antioxidants [ 13 , 14 , 15 , 16 ], and possess anticancer activity [ 17 , 18 , 19 , 20 ].…”
Section: Introductionmentioning
confidence: 99%
“…Dual inhibitors of the two targets are considered promising scaffolds for treatment of solid tumors. 18–20 Cabozantinib is a potent inhibitor of c-MET and VEGFR-2 for patients with medullary thyroid cancer. 21 Recently, clinical trials showed a small-molecule dual inhibitor, tivozanib.…”
Section: Introductionmentioning
confidence: 99%